CA2494801A1 - Composition medicamenteuse contenant un inhibiteur de hmg-coa reductase - Google Patents

Composition medicamenteuse contenant un inhibiteur de hmg-coa reductase Download PDF

Info

Publication number
CA2494801A1
CA2494801A1 CA002494801A CA2494801A CA2494801A1 CA 2494801 A1 CA2494801 A1 CA 2494801A1 CA 002494801 A CA002494801 A CA 002494801A CA 2494801 A CA2494801 A CA 2494801A CA 2494801 A1 CA2494801 A1 CA 2494801A1
Authority
CA
Canada
Prior art keywords
nitric oxide
hmg
vascular endothelial
coa reductase
oryzanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002494801A
Other languages
English (en)
Inventor
Tatsuhito Kondo
Ikuo Takagi
Masato Nakayama
Yasuhiro Torizumi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Publication of CA2494801A1 publication Critical patent/CA2494801A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne la recherche d'une composition médicamenteuse permettant d'activer la synthèse d'oxyde d'azote de l'endothélium vasculaire et/ou de maintenir ou d'augmenter la concentration d'oxyde d'azote de l'endothélium vasculaire dans le sang, ou bien d'une composition médicamenteuse permettant d'augmenter les lipides sanguins. A cet effet, on a mis au point une composition médicamenteuse qui contient un inhibiteur de HMG-CoA réductase, du .gamma.-oryzanol et/ou des thiamines.
CA002494801A 2002-08-02 2003-08-01 Composition medicamenteuse contenant un inhibiteur de hmg-coa reductase Abandoned CA2494801A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2002225979 2002-08-02
JP2002-225979 2002-08-02
JP2002-260719 2002-09-06
JP2002260719 2002-09-06
PCT/JP2003/009835 WO2004012740A1 (fr) 2002-08-02 2003-08-01 Composition medicamenteuse contenant un inhibiteur de hmg-coa reductase

Publications (1)

Publication Number Publication Date
CA2494801A1 true CA2494801A1 (fr) 2004-02-12

Family

ID=31497621

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002494801A Abandoned CA2494801A1 (fr) 2002-08-02 2003-08-01 Composition medicamenteuse contenant un inhibiteur de hmg-coa reductase

Country Status (5)

Country Link
JP (1) JP2010150288A (fr)
AU (1) AU2003252358A1 (fr)
CA (1) CA2494801A1 (fr)
TW (1) TW200409635A (fr)
WO (1) WO2004012740A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12239644B2 (en) 2018-11-02 2025-03-04 Kyungpook National University Industry-Academic Cooperation Foundation Composition for prevention or treatment of macular degeneration
KR102741077B1 (ko) * 2022-04-20 2024-12-10 국립목포대학교산학협력단 감마-오리자놀을 포함하는 판막증 예방 또는 치료용 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54135740A (en) * 1978-04-13 1979-10-22 Otsuka Nobuhiro Method of dissolving oryznol to greases or their products
EP0904082A4 (fr) * 1996-04-17 2001-09-26 Merck & Co Inc Therapie d'association destinee a reduire les risques lies a une maladie cardio-vasculaire
EP1792616B1 (fr) * 1997-07-31 2009-12-16 Abbott Respiratory LLC Composition contenant un inhibiteur de réductase HMG-CoA et un composé d'acide nicotinique destiné au traitement d'hyperlipidémie
JP3597437B2 (ja) * 2000-02-10 2004-12-08 日清オイリオグループ株式会社 血中脂質改善機能を有する食用油脂
CN1250212C (zh) * 2000-10-23 2006-04-12 三共株式会社 血中脂类改善剂组合物

Also Published As

Publication number Publication date
WO2004012740A1 (fr) 2004-02-12
AU2003252358A1 (en) 2004-02-23
HK1077230A1 (zh) 2006-02-10
JP2010150288A (ja) 2010-07-08
TW200409635A (en) 2004-06-16

Similar Documents

Publication Publication Date Title
EP1510208A1 (fr) Compositions pharmaceutiques comprenant une combinaison de metformine et de statine
JP2013035871A (ja) 炎症性肺疾患の治療のためのＨＭＧ−ＣｏＡレダクターゼインヒビターとホスホジエステラーゼ４インヒビターとの組合せ物
JP2002518448A (ja) 高血中コレステロールを治療する組成物および方法
US20150272944A1 (en) Novel triglyceride reducing agent
JP2010077162A (ja) 血中ホモシステイン低下のための医薬組成物
US20050187204A1 (en) Medicinal composition for lowering blood lipid level
CA2679416A1 (fr) Polytherapie, composition et methodes de traitement de troubles cardiovasculaires
US20080070938A1 (en) Medicinal composition for mitigating blood lipid or lowering blood homocysteine
US20050182036A1 (en) Medicinal composition containing an HMG-CoA reductase inhibitor
CA2494801A1 (fr) Composition medicamenteuse contenant un inhibiteur de hmg-coa reductase
US6916849B2 (en) Compositions for improving lipid content in the blood
JP2003503342A (ja) ＭＴＰ阻害剤とＨＭＧ−ＣｏＡ還元酵素阻害剤との組み合わせ並びに薬剤におけるその使用
JP4607436B2 (ja) ＨＭＧ−ＣｏＡリダクターゼ阻害剤を含有する医薬組成物
AU2004233693B2 (en) Adiponectin production enhancer
JPWO2001085155A1 (ja) 動脈硬化抑制方法及び組成物
US20040023919A1 (en) Blood lipid ameliorant composition
AU2001282541B2 (en) Medicinal compositions
US20030216357A1 (en) Compositions for improving lipid content in the blood
CA2494916A1 (fr) Composition medicale abaissant le taux de lipides sanguins
CN100415235C (zh) 含有HMG-CoA还原酶抑制剂的药物组合物
JP4454985B2 (ja) 血液脂質を低下させるための医薬組成物
EP1618893A1 (fr) Composition activant l'aptitude a consommer du sucre
JP4896501B2 (ja) 血中遊離脂肪酸低下作用を有する医薬組成物
JP4611622B2 (ja) 血中脂質改善又は血中ホモシステイン低下のための医薬組成物
HK1077230B (en) Medicinal composition hmg-coa reductase inhibitor

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued